anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ENGAGES CANADA is a parallel study to the ENGAGES study which has been published in JAMA, DOI:10.1001/jama.2019.5161. Due to the difference in practice models and types of anesthesia principles, ENGAGES CANADA is an important study. Delirium is a relatively common postoperative complication in the geriatric population, affecting 20% to 70% of surgical patients over the age of 60. Delirium manifests as confusion, inattention and the inability to think logically, and may affect the patient's postoperative healing and rehabilitation. It is associated with persistent cognitive decline, longer hospital stay, increased incidence of injurious falls, and increased mortality. Patients undergoing major cardiac surgery are at a significant risk of postoperative delirium. To date, there is no proven method to prevent postoperative delirium in this patient population and often delirious events remain unrecognized. Randomized controlled studies in diverse surgical patient populations suggest that intraoperative electroencephalography (EEG) guidance during general anesthesia may decrease postoperative delirium and adverse postoperative outcomes. Patients who experience postoperative delirium report persistently decreased quality of life and it is a risk factor for incident psychiatric disorders and psychotropic medication use. One potential key mechanism in the relationship between delirium and incident psychiatric illness may be the experience of dissociation (disturbed awareness, impaired memory, or altered perceptions) in the perioperative period in those who are delirious. The co-occurrence of psychiatric illness and delirium can put older adults at greater risk of negative long terms effect such as functional decline. This study will compare the effectiveness of two anesthetic protocols in reducing postoperative delirium and postoperative health-related quality of life in a high risk population.We expect that EEG-guided anesthetic management of patients during their operative procedure will result in improved health-related outcomes, specifically decreased incidence of postoperative delirium and improved postoperative mental and physical health outcomes.
It comprises at least one agent with keratolytic and cerumenolytic cleaning action, an agent with bactericidal activity, a yeast control agent and an anti-irritant and anti-itch agent. Furthermore, it can comprise at least one agent with cerumenolytic enhancing action, at least one plant extract with antiseptic and healing action and/or at least one deodorant agent. The agent with keratolytic and cerumenolytic cleaning action is lactic acid, salicylic acid or a mixture of both. The bactericidal agent is extract of Cetraria islandica. The yeast control agent is lactic acid, salicylic acid, or a mixture of both. The anti-irritant and antipruritic agent is a plant extract of Cucumis sativus. The agent with cerumenolytic enhancing action is oleic acid. The plant extract is Mimosa tenuiflora extract, Cetraria islandica extract, Chamomilla recutita extract or a mixture of them. The deodorant agent is extract of Cetraria islandica. (Machine-translation by Google Translate, not legally binding)
Objective methods for diagnosing cancer or a predisposition to developing cancer, particularly lung cancer are described herein. The present invention provides a diagnostic method that utilizes the expression level of C6orf167 as an index of cancer. The present invention further provides methods of screening for therapeutic substances useful in the treatment of cancer, e.g. lung cancer. The invention further provides methods of inhibiting the cancer cell growth and either or both of treating and preventing cancer. The invention also features double stranded molecules against C6orf167 gene and an inhibitory polypeptide for NFKBIL2, as well as vector encoding them and compositions containing them.
This study aimed to investigate the mid-to-long-term surgical outcomes of open reduction and internal fixation (ORIF) using a hybrid locking plate/cable technique for the treatment of Vancouver type B1 and type C periprosthetic femoral fractures (PPFs) in a consecutive group of patients from a single tertiary referral center. Twenty-five patients (25 PPFs; 17 female, 8 male) in whom a Vancouver type B1 or type C PPF was diagnosed and treated by a hybrid locking plate/cable technique from 2005 to 2016 were included in the study. Patients' functional status was categorized into 4 groups based on the Harris Hip Score (HHS) at the final follow-up: 70=poor result; 70-80=fair; 80-90=good, and 90-100=excellent. Intraand postoperative complications were also recorded. PPF union was defined clinically as the patient's ability to bear full weight with or without assistance and radiographically as the presence of a callus bridging the fracture. Subgroup analyses were conducted according to the Vancouver classification and type of fixation regarding the HHS and time to union. The mean age was 57 ± 16.6 (range, 17-82) years at the time of the primary hip replacement and 64 ± 18.7 (range, 24-88) years at the time of PPF. The mean follow-up was 5.6 ± 3.3 (range, 2-14) years from primary procedure to PPF and 6.5 ± 4.1 (range, 3-15) years following PPF. There were 7 type B1 and 18 type C PPFs. At the final follow-up, the mean HHS was 71 ± 7.74 (range, 57-89). According to HHS, functional results were poor in 8 patients, fair in 14 patients, and good in 3 patients. No major intra- or postoperative complications were noted. Fracture union was achieved in all patients without complications at an average of 13 ± 4.9 (range, 6-24) weeks. In subgroup analysis, while no significant differences were observed in the HHS (P=.87 for the Vancouver type, P=.96 for the type of fixation), time to union differed among groups. Time to union was significantly shorter in type B1 than in type C PPFs (P=.006). Time to union was considerably shorter in the uncemented group compared to the cemented one (P=.017). Adding cables to the locking plate can provide adequate stability to preserve fracture alignment and achieve bony union in Vancouver type B1 and C PPFs. Although union can be achieved by ORIF in such patients, a longer union time may be required for PPFs in the setting of a cemented femoral stem or Vancouver type C. Level IV, Therapeutic study.
BACKGROUND AND AIMS: NASH represents a severe stage of fatty liver disease characterized by hepatocyte injury, inflammation, and liver fibrosis. Myeloid-derived innate immune cells, such as macrophages and dendritic cells, play an important role in host defense and disease pathogenesis. Despite this, the nature of transcriptomic reprogramming of myeloid cells in NASH liver and its contribution to disease progression remain incompletely defined.
APPROACH AND RESULTS: In this study, we performed bulk and single-cell RNA sequencing (sc-RNA seq) analysis to delineate the landscape of macrophage and dendritic cell transcriptomes in healthy and NASH livers. Our analysis uncovered cell type-specific patterns of transcriptomic reprogramming on diet-induced NASH. We identified brain-abundant membrane-attached signal protein 1 (Basp1) as a myeloid-enriched gene that is markedly induced in mouse and human NASH liver. Myeloid-specific inactivation of Basp1 attenuates the severity of diet-induced NASH pathologies, as shown by reduced hepatocyte injury and liver fibrosis in mice. Mechanistically, cultured macrophages lacking Basp1 exhibited a diminished response to pro-inflammatory stimuli, impaired NLRP3 inflammasome activation, and reduced cytokine secretion.
CONCLUSIONS: Together, these findings uncover Basp1 as a critical regulator of myeloid inflammatory signaling that underlies NASH pathogenesis.
The invention relates to a new purpose of an extracting ingredient of leaves of hippophaes rhamnoides L., in particular to medicine and healthcare products made from leaves of hippophaes rhamnoides L. for replenishing estrogen. The invention also relates to leaves of the hippophaes rhamnoides L. used as healthcare tea for replenishing progynon. The inventor discovers that the extractive of the leaves of the hippophaes rhamnoides L. contains the progynon by investigation, the Latin name of the progynon is Estradiol, and the molecular formula of the progynon is C18H24O2. Consequently, the new purpose for curing an estrogen replenishing deficiency disease is developed, namely, the extractive of the leaves of the hippophaes rhamnoides L. can be made into the medicine and the health products for replenishing the estrogen, and the leaves of the hippophaes rhamnoides L. is used as the healthcare tea for replenishing the progynon. The invention has the advantages of no harm on the human body, no toxic or side effect, safety and reliability, can effectively increase the progynon in female bodies, is suitable for taking for a long time, can effectively protect the health of middle-aged and old women, and can effectively increase the life quality and the living quality of females. The invention serves as a new preparation for replenishing the progynon and has better social benefit and economic benefit.
Following consent and collection of standardized phenotypic data, probands and biological parents will undergo WES with variant analysis conducted utilizing primary gene lists based on referring clinical indication. After results provision and follow up 6-12 months later, clinical utility will be assessed in those with a positive result (pathogenic or likely pathogenic variant) and those with negative results (no variant returned or a VUS) using specific outcomes at each site to examine effectiveness for both the child and family.
PURPOSE:To provide new compounds useful as an alpha2-adrenalin-antagonist and an antianxiety agent. CONSTITUTION:Compounds of the formula (R is lower alkyl or phenyl or thiophenyl which may be respectively substituted with halogen), e.g. yohimbine methanesulfonate. The compound of the formula can be obtained, e.g. by reacting (+)-yohimbine on the market with an amine (e.g. triethylamine) and a sulfonyl chloride compound in a solvent such as THF preferably in an atmosphere of nitrogen gas at room temperatures. Showing a remarkably strong affinity to l alpha2-adrenalin receptor or showing a highly selective affinity to alpha2- adrenalin receptor and showing a strong affinity to 5-HT1A receptor.
Lidocaine HCI (1.7mL) 2% concentration with epinephrine (1:100,000) is the control agent. It exists in liquid form in cartridges. Lidocaine is a FDA approved marketed anesthetic drug.
1. Technical Result Increase in efficiency of treatment of diseases caused by integrin receptor. 2. Essence Compounds and derivatives, the structural formulas of which are provided in the description, are integrin receptor antagonists, more particularly, the antagonists of the integrin receptors alpha vbeta3, alpha vbeta5 and alpha vbeta6. Pharmaceutical compositions containing them and methods of treating bone resorption, osteoporosis, vascular restenosis, diabetic retinopathy, macular degeneration, inflammation and diseases caused by tumor growth and metastasis are disclosed. 3. Field of Application Medicine.
PURPOSE: A composition containing Lycoris aurea extract, fraction thereof, or compound isolated from the same for preventing or treating dementia is provided to apply in a single method and in a cocktail method with conventional therapeutic agent such as tacrine, donepezil, and rivastigmine. CONSTITUTION: A composition for preventing or treating dementia contains Lycoris aurea extract as an active ingredient. The Lycoris aurea extract is isolated using water or low alcohol of C1-C4. The Lycoris aurea extract is also an acetic acid ethyl fraction, butanol fraction, or mixture thereof. The composition for preventing or treating dementia contains lycoricidine of chemical formula 1, lycoricidinol of chemical formula 2, or pharmaceutically acceptable salt as an active ingredient. The dementia is Alzheimer's disease. A health food for preventing or treating dementia contains the composition.
The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d). Supplementation of multivitamins and minerals was provided per day.
The purpose of this multi-site RCT is to determine the effectiveness of the MAC group intervention on reducing psychotic disorder symptomatology (primary outcome) as well as promoting quality of life, critical skills for recovery and decreasing mental health service utilization (secondary outcomes) for transitional aged youth (16-25 years old) experiencing early psychosis. This study is being run at five southern Ontario Early Psychosis Intervention (EPI) sites with Prevention and Early Intervention Program for Psychoses (PEPP) at London Health Sciences Centre (LHSC) being the lead site. Three of the larger sites (located in London, Kitchener-Waterloo, and Hamilton Ontario) are following the RCT design, while the two smaller sites (located in Chatham-Kent and Sarnia, Ontario) are participating in a pre-post design.

For the three RCT sites we aim to recruit 20-24 participants, and for the pre-post sites we aim to recruit 10 participants (total n=92 participants). Participants at the RCT sites will be randomized into Group-A (n = 12; immediate treatment intervention group) or Group-B (n = 12; delayed treatment intervention group). Group-A will receive the MAC intervention at the onset of the study, while Group-B will receive treatment as usual (TAU). Group-B will have the option of receiving the MAC intervention approximately 6 months after the onset of the study. At all times during this study, participants who are receiving the MAC intervention will also be able to continue receiving TAU. Both groups will be assessed with a battery of quantitative measures at baseline (T1), three months later (i.e., immediately post-MAC intervention) (T2), and again three months post-MAC intervention (T3). The measures include interview assessments of psychotic disorder symptoms, and self-report measures of affect, self-esteem, quality of life, coping strategies, assertiveness, social functioning, mindfulness and cognitive skills. In addition, healthcare utilization records for the 6 months preceding MAC intervention onset and for the 6 month duration of the study (3 month MAC intervention + 3 month post-MAC intervention follow-up period) will be collected. Researchers conducting symptom assessment interviews and data analysis will be blinded to the group membership of participants. For the two pre-post sites, all 10 participants will receive the MAC intervention immediately. All 10 participants will complete T1, T2, and T3 assessments and their healthcare utilization records will also be collected.

Based on the pilot study at PEPP-LHSC, and based on previous findings of Mindfulness Based Interventions for psychoses in the literature, we are expecting that participation in the MAC intervention will result in improvement in the following areas: psychotic symptomology (including affective symptoms), mindfulness skills, quality of life, measures of recovery (self-esteem, perceived recovery), perceived coping, assertiveness, social functioning, cognitive skills, and a reduction in healthcare service utilization (e.g., emergency room visits, inpatient admissions/length of hospitalization).
Common choanal atresia repair techniques include puncture and dilatation of the atretic area. Endoscopic drilling combined with dissection of the atretic plate and its surrounding structures has been introduced more recently. The approaches have been through transnasal, transpalatal, and transseptal routes. Each of which have experienced varying popularity through time. Regardless of the access route and repair technique used, re-stenosis is a common postoperative complication. To prevent re-stenosis and subsequent re-operation, many authors advocate meticulous preservation of mucosa for use as flaps, which in most cases are combined with postoperative stenting. However, stenting, is controversial

The surgical procedure is performed under general anesthesia. Preoperatively, cotton pledgets soaked in a solution of topical vasoconstrictors are placed against the nasal mucosa for topical decongestion. Local anesthesia is infiltrated into the nasal septum, the atretic plate, the middle turbinate, and the superolateral nasal wall. An endoscopic view of the surgical field is maintained at all times during the procedure using a 4-mm nasal endoscope with 0-degree or 30-degree visual angulation. Firstly, mucosa is elevated bilaterally from the underlying cartilaginous and bony septum on both sides. Then the posterior half of the septum including the vomer is removed using Blakesley forceps and a 1-mm or 2.5-mm diamond burr. After that, the flaps are fashioned using the preserved mucosa. At last, the flaps are secured in position with a thin layer of fibrin glue or gel foam. No packing or stenting is used. The patient is extubated immediately following the procedure and early oral feeding encouraged. The intended length of stay is overnight.
Postoperative adhesions, a prevalent complication following abdominal surgery, affect 90% of patients undergoing abdominal surgical procedures. Currently, the primary approach to prevent postoperative adhesions involves physical isolation of the surgical site and surrounding tissues using a hydrogel; however, this method represents a rudimentary strategy. Herein, considering the impact of oxidative stress and free radicals on postoperative adhesion during wound healing, an injectable antioxidant hydrogel, named PU-OHA-D, was successfully synthesized, which is formed by the crosslinking of dopamine-modified oxidized hyaluronic acid (OHA-D) and dihydrazide-terminated polyurethane (PU-ADH) through hydrazone bonding. PU-OHA-D hydrogel possesses versatile characteristics such as rapid gel formation, injectability, self-repair capability and biodegradability. Additionally, they exhibit an excellent ability to clear free radicals and superior tissue adhesion. PU-OHA-D can be injected in situ to form a hydrogel to prevent abdominal wall-cecum adhesion. Importantly, it can effectively eliminate free radicals and inhibit oxidative stress at the wound site. Thereby, it leads to collagen physiological degradation and prevents the occurrence of postoperative adhesions. The bioinspired hydrogel demonstrates its great potential in preventing postoperative adhesion and promoting wound healing.
The invention relates to a compound, which comprises the cytotoxic agents microcystin and nodularin. More specifically, the invention is related to a modified microcystin and/or nodularin compound comprising one or more modified substrates, wherein one or more modified substrates comprise an anchor group directly accessible or transformable for use in conjugation chemistry (incl. click chemistry), for the attachment of a targeting moiety. This invention is in the field of cancer treatment. It is in the field of toxins for use in cancer treatment. The modified cytotoxic agents may be used for the therapy of various diseases.
The treatment pneumococcal vaccine was developed by Yunnan Walvax Biotech Co., Ltd (Walvax) China, is a sterile, liquid vaccine for intramuscular or subcutaneous injection. It consists of a mixture of highly purified capsular polysaccharides from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae, including the six serotypes that most frequently cause invasive drug-resistant pneumococcal infections among children and adults in China. The dose of vaccine is an individual with a 0.5ml dose contains 23 kinds of pneumococcal polysaccharide serotypes each 25μg, and does not contain any preservatives. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with amitriptyline hydrochloride and should counsel them in its appropriate use. A patient Medication Guide about “Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions” is available for amitriptyline hydrochloride. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking amitriptyline hydrochloride.
OBJECTIVES: I. Determine the activity and toxicities of gemcitabine in elderly patients with non-small cell lung cancer. II. Determine the activity and toxicity of the combination of gemcitabine and vinorelbine in these patients. III. Compare the survival rate and quality of life of these patients treated with combination chemotherapy versus single agent chemotherapy. IV. Compare objective response and time to progression of these patients treated with these chemotherapy regimens. V. Compare the toxicities of these three regimens in these patients. VI. Compare the number of hospitalizations, palliative radiation therapies, antibiotic therapies, corticosteroid therapies, analgesic therapies, and hematopoietic growth factor therapies needed for these patients treated with these chemotherapy regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified by center, stage of disease (IIIB vs IV), and performance status (0 vs 1 vs 2). Patients are randomized to one of three treatment arms. Patients receive either vinorelbine IV, gemcitabine IV, or both on days 1 and 8 of each 21 day course. Patients who achieve an objective response or stable disease after 3 courses receive 3 more courses (for a total of 6 courses). Quality of life is assessed before treatment, after course 4 (or 3 weeks after course 3, if therapy is stopped), and at 21 days after course 6 (or 12 weeks after course 3).

PROJECTED ACCRUAL: A total of 630 patients (210 patients per arm) will be accrued for this study.
The implementation strategy will be tested in a stepped wedge cluster randomized trial which is based on a random sequential roll-out of the CHANGE implementation strategy to all participating NHs (n=20) for comparison. All groups (hence all NHs) start with the control situation (no CHANGE implementation activities) at the beginning of the study. At each time point, a new group of five NHs crosses over from the control situation to the implementation situation. Each group will start the implementation phase of 4 months at a different time point, directly after one of the measurements periods (Point of Time (PT) 0, PT1, PT2, PT3, PT4, PT5). The time point a group crosses over is randomized (over the groups).